| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scaphoid Bone | 4 | 2022 | 19 | 2.490 |
Why?
|
| Radius Fractures | 8 | 2019 | 25 | 2.140 |
Why?
|
| Elbow Joint | 11 | 2020 | 115 | 2.130 |
Why?
|
| Surgical Flaps | 7 | 2015 | 50 | 1.940 |
Why?
|
| Range of Motion, Articular | 16 | 2022 | 602 | 1.770 |
Why?
|
| Elbow | 6 | 2020 | 41 | 1.730 |
Why?
|
| Radius | 6 | 2018 | 33 | 1.510 |
Why?
|
| Tendon Injuries | 4 | 2022 | 163 | 1.490 |
Why?
|
| Wrist Joint | 6 | 2022 | 56 | 1.450 |
Why?
|
| Arthrodesis | 7 | 2022 | 33 | 1.410 |
Why?
|
| Fracture Fixation, Internal | 6 | 2020 | 57 | 1.390 |
Why?
|
| Fractures, Comminuted | 4 | 2017 | 8 | 1.280 |
Why?
|
| Muscle, Skeletal | 5 | 2020 | 337 | 1.270 |
Why?
|
| Humans | 54 | 2022 | 23569 | 1.060 |
Why?
|
| Orthopedics | 2 | 2018 | 83 | 1.050 |
Why?
|
| Tendons | 3 | 2022 | 183 | 0.990 |
Why?
|
| Treatment Outcome | 18 | 2020 | 3095 | 0.950 |
Why?
|
| Humeral Fractures | 2 | 2020 | 20 | 0.930 |
Why?
|
| Orthopedic Procedures | 5 | 2020 | 240 | 0.930 |
Why?
|
| Retrospective Studies | 19 | 2022 | 3122 | 0.900 |
Why?
|
| Soft Tissue Injuries | 4 | 2014 | 14 | 0.870 |
Why?
|
| Osteoarthritis | 2 | 2022 | 289 | 0.850 |
Why?
|
| Fractures, Ununited | 2 | 2017 | 15 | 0.820 |
Why?
|
| Bone Screws | 4 | 2017 | 130 | 0.820 |
Why?
|
| Adult | 20 | 2022 | 7178 | 0.800 |
Why?
|
| Finger Injuries | 1 | 2022 | 2 | 0.780 |
Why?
|
| Male | 28 | 2020 | 12776 | 0.780 |
Why?
|
| Joint Instability | 5 | 2020 | 325 | 0.770 |
Why?
|
| Bone Transplantation | 4 | 2017 | 156 | 0.760 |
Why?
|
| Reoperation | 6 | 2020 | 767 | 0.760 |
Why?
|
| Hand | 4 | 2019 | 39 | 0.730 |
Why?
|
| Arthroplasty, Replacement, Elbow | 2 | 2020 | 6 | 0.730 |
Why?
|
| Tennis Elbow | 2 | 2018 | 13 | 0.700 |
Why?
|
| Carpal Bones | 2 | 2019 | 6 | 0.680 |
Why?
|
| Ulna | 3 | 2018 | 29 | 0.680 |
Why?
|
| Middle Aged | 21 | 2022 | 8155 | 0.680 |
Why?
|
| Forearm Injuries | 2 | 2010 | 5 | 0.640 |
Why?
|
| Golf | 1 | 2019 | 4 | 0.640 |
Why?
|
| Muscle Strength | 1 | 2020 | 102 | 0.630 |
Why?
|
| Ossification, Heterotopic | 3 | 2011 | 33 | 0.620 |
Why?
|
| Female | 24 | 2020 | 13266 | 0.620 |
Why?
|
| Yoga | 1 | 2019 | 10 | 0.620 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 271 | 0.620 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2018 | 16 | 0.590 |
Why?
|
| Tendinopathy | 2 | 2016 | 41 | 0.590 |
Why?
|
| Physician Assistants | 1 | 2018 | 10 | 0.580 |
Why?
|
| Nurse Practitioners | 1 | 2018 | 34 | 0.570 |
Why?
|
| Consumer Health Information | 1 | 2018 | 2 | 0.570 |
Why?
|
| Elbow Prosthesis | 1 | 2017 | 2 | 0.560 |
Why?
|
| Radiography | 11 | 2018 | 556 | 0.560 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2014 | 10 | 0.560 |
Why?
|
| Hand Injuries | 2 | 2014 | 11 | 0.560 |
Why?
|
| Young Adult | 7 | 2020 | 1747 | 0.550 |
Why?
|
| Patient Preference | 1 | 2018 | 33 | 0.550 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 177 | 0.550 |
Why?
|
| Forecasting | 1 | 2017 | 80 | 0.540 |
Why?
|
| Internet | 1 | 2018 | 82 | 0.530 |
Why?
|
| DNA Damage | 3 | 2006 | 26 | 0.520 |
Why?
|
| Ulnar Nerve Compression Syndromes | 1 | 2016 | 2 | 0.520 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.520 |
Why?
|
| Fractures, Bone | 1 | 2017 | 70 | 0.520 |
Why?
|
| Adolescent | 7 | 2018 | 1953 | 0.490 |
Why?
|
| Aged | 13 | 2020 | 7586 | 0.470 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2015 | 559 | 0.470 |
Why?
|
| DNA Methylation | 1 | 2016 | 129 | 0.470 |
Why?
|
| Knee Prosthesis | 2 | 2015 | 203 | 0.460 |
Why?
|
| Arthroscopy | 3 | 2018 | 742 | 0.460 |
Why?
|
| Arthritis | 2 | 2011 | 45 | 0.430 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 127 | 0.410 |
Why?
|
| Fractures, Malunited | 2 | 2010 | 4 | 0.400 |
Why?
|
| External Fixators | 2 | 2011 | 7 | 0.400 |
Why?
|
| Wrist Injuries | 2 | 2012 | 17 | 0.400 |
Why?
|
| Allografts | 3 | 2020 | 149 | 0.390 |
Why?
|
| Fracture Fixation | 2 | 2010 | 20 | 0.390 |
Why?
|
| Triangular Fibrocartilage | 1 | 2012 | 7 | 0.380 |
Why?
|
| Joint Dislocations | 2 | 2010 | 50 | 0.370 |
Why?
|
| Ulna Fractures | 1 | 2011 | 7 | 0.360 |
Why?
|
| Bone Nails | 2 | 2009 | 13 | 0.360 |
Why?
|
| Supination | 3 | 2020 | 17 | 0.350 |
Why?
|
| Bone Plates | 3 | 2020 | 41 | 0.350 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2006 | 20 | 0.350 |
Why?
|
| Carpometacarpal Joints | 1 | 2010 | 2 | 0.340 |
Why?
|
| Thumb | 1 | 2010 | 5 | 0.340 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 3770 | 0.310 |
Why?
|
| Ligaments, Articular | 1 | 2010 | 89 | 0.310 |
Why?
|
| Arthroplasty | 1 | 2010 | 117 | 0.310 |
Why?
|
| Tibial Fractures | 1 | 2009 | 7 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 606 | 0.300 |
Why?
|
| Histones | 2 | 2006 | 28 | 0.300 |
Why?
|
| Connective Tissue Diseases | 1 | 2008 | 7 | 0.300 |
Why?
|
| Fracture Healing | 2 | 2017 | 32 | 0.270 |
Why?
|
| Femoral Fractures | 1 | 2007 | 32 | 0.270 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2007 | 50 | 0.270 |
Why?
|
| Acetabulum | 1 | 2009 | 192 | 0.270 |
Why?
|
| Regression Analysis | 2 | 2022 | 220 | 0.260 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 1493 | 0.260 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 64 | 0.260 |
Why?
|
| Cell Cycle Proteins | 2 | 2006 | 16 | 0.260 |
Why?
|
| Hand Strength | 3 | 2015 | 49 | 0.260 |
Why?
|
| Cell Cycle | 3 | 2017 | 33 | 0.250 |
Why?
|
| Prosthesis Failure | 1 | 2009 | 424 | 0.250 |
Why?
|
| Joint Prosthesis | 3 | 2013 | 75 | 0.240 |
Why?
|
| Wrist | 2 | 2022 | 16 | 0.230 |
Why?
|
| Hip Prosthesis | 1 | 2009 | 443 | 0.220 |
Why?
|
| Caspases | 1 | 2004 | 22 | 0.220 |
Why?
|
| Wound Healing | 3 | 2015 | 123 | 0.220 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 104 | 0.210 |
Why?
|
| United States | 2 | 2020 | 1837 | 0.210 |
Why?
|
| Recovery of Function | 4 | 2016 | 255 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2020 | 1535 | 0.210 |
Why?
|
| Apoptosis | 1 | 2004 | 198 | 0.210 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 1046 | 0.200 |
Why?
|
| Rupture | 2 | 2020 | 86 | 0.200 |
Why?
|
| Postoperative Complications | 2 | 2011 | 837 | 0.200 |
Why?
|
| Finger Joint | 1 | 2022 | 5 | 0.200 |
Why?
|
| Tissue Adhesions | 1 | 2022 | 9 | 0.190 |
Why?
|
| Cluster Analysis | 1 | 2022 | 41 | 0.190 |
Why?
|
| Time Factors | 4 | 2017 | 1295 | 0.190 |
Why?
|
| Traction | 1 | 2022 | 28 | 0.190 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2009 | 699 | 0.180 |
Why?
|
| Sports | 1 | 2022 | 42 | 0.180 |
Why?
|
| Return to Sport | 1 | 2022 | 111 | 0.170 |
Why?
|
| Extracellular Traps | 2 | 2017 | 3 | 0.170 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2020 | 4 | 0.160 |
Why?
|
| Return to Work | 1 | 2020 | 40 | 0.160 |
Why?
|
| Telemedicine | 1 | 2021 | 85 | 0.160 |
Why?
|
| Humerus | 1 | 2020 | 92 | 0.160 |
Why?
|
| Medicare | 1 | 2020 | 107 | 0.160 |
Why?
|
| Neurons | 2 | 2012 | 273 | 0.160 |
Why?
|
| Animals | 6 | 2016 | 3311 | 0.150 |
Why?
|
| Arthroplasty, Replacement | 2 | 2013 | 129 | 0.150 |
Why?
|
| Mycoses | 1 | 2019 | 20 | 0.150 |
Why?
|
| Disability Evaluation | 2 | 2020 | 220 | 0.150 |
Why?
|
| Recurrence | 2 | 2018 | 276 | 0.150 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 14 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2019 | 51 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2019 | 52 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2020 | 391 | 0.150 |
Why?
|
| Professional Role | 1 | 2018 | 28 | 0.140 |
Why?
|
| Office Visits | 1 | 2018 | 11 | 0.140 |
Why?
|
| Cyclins | 1 | 2017 | 5 | 0.140 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 9 | 0.140 |
Why?
|
| Autoimmunity | 1 | 2017 | 12 | 0.140 |
Why?
|
| Pain Measurement | 3 | 2021 | 429 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2018 | 96 | 0.140 |
Why?
|
| Saccharomyces cerevisiae Proteins | 3 | 2006 | 13 | 0.130 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2016 | 3 | 0.130 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2016 | 3 | 0.130 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 16 | 0.130 |
Why?
|
| Enthesopathy | 1 | 2016 | 2 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 17 | 0.130 |
Why?
|
| Achilles Tendon | 1 | 2016 | 12 | 0.130 |
Why?
|
| Debridement | 2 | 2020 | 74 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 102 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 16 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 52 | 0.130 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 528 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 85 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2018 | 202 | 0.130 |
Why?
|
| G1 Phase | 2 | 2006 | 16 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2016 | 89 | 0.120 |
Why?
|
| Neutrophils | 1 | 2016 | 93 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 152 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 179 | 0.120 |
Why?
|
| Sarcoma | 1 | 2018 | 142 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 364 | 0.120 |
Why?
|
| Prosthesis Design | 2 | 2013 | 394 | 0.110 |
Why?
|
| Forearm | 2 | 2018 | 18 | 0.100 |
Why?
|
| Physical Examination | 2 | 2011 | 94 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 203 | 0.100 |
Why?
|
| Carpal Joints | 1 | 2013 | 5 | 0.100 |
Why?
|
| Ilium | 2 | 2018 | 28 | 0.100 |
Why?
|
| Ribosomes | 1 | 2012 | 1 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2012 | 131 | 0.100 |
Why?
|
| Transcriptome | 1 | 2012 | 55 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 908 | 0.090 |
Why?
|
| Mice | 5 | 2016 | 1249 | 0.090 |
Why?
|
| Exercise Therapy | 1 | 2012 | 85 | 0.090 |
Why?
|
| Cadaver | 2 | 2011 | 305 | 0.090 |
Why?
|
| Cost Savings | 1 | 2011 | 29 | 0.090 |
Why?
|
| Arm | 2 | 2022 | 69 | 0.090 |
Why?
|
| Eating | 1 | 2011 | 46 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 58 | 0.090 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 65 | 0.080 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2010 | 2 | 0.080 |
Why?
|
| Neuroma | 1 | 2010 | 2 | 0.080 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2010 | 18 | 0.080 |
Why?
|
| Wound Infection | 1 | 2010 | 6 | 0.080 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2010 | 15 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 1 | 0.080 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2010 | 20 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 18 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 35 | 0.080 |
Why?
|
| Fractures, Open | 1 | 2009 | 1 | 0.080 |
Why?
|
| Protein-Serine-Threonine Kinases | 2 | 2006 | 2 | 0.080 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2009 | 7 | 0.080 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2006 | 8 | 0.080 |
Why?
|
| Arthralgia | 1 | 2010 | 108 | 0.080 |
Why?
|
| Device Removal | 1 | 2009 | 68 | 0.070 |
Why?
|
| Tendon Transfer | 1 | 2008 | 15 | 0.070 |
Why?
|
| Osteotomy | 1 | 2010 | 128 | 0.070 |
Why?
|
| Torticollis | 1 | 2008 | 7 | 0.070 |
Why?
|
| Hospitalization | 1 | 2011 | 293 | 0.070 |
Why?
|
| Hip Dislocation, Congenital | 1 | 2008 | 4 | 0.070 |
Why?
|
| Bone Cements | 1 | 2009 | 79 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 168 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 74 | 0.070 |
Why?
|
| Torque | 1 | 2007 | 18 | 0.070 |
Why?
|
| Mutation | 2 | 2006 | 330 | 0.070 |
Why?
|
| Rotation | 1 | 2007 | 116 | 0.070 |
Why?
|
| Fungal Proteins | 1 | 2006 | 5 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2016 | 556 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2007 | 505 | 0.060 |
Why?
|
| Smoking | 1 | 2007 | 168 | 0.060 |
Why?
|
| Radiation, Ionizing | 1 | 2005 | 2 | 0.060 |
Why?
|
| Protein Methyltransferases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 9 | 0.060 |
Why?
|
| S Phase | 1 | 2005 | 11 | 0.060 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 17 | 0.060 |
Why?
|
| Methylation | 1 | 2005 | 10 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 19 | 0.060 |
Why?
|
| Lysine | 1 | 2005 | 14 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2005 | 39 | 0.060 |
Why?
|
| Epitopes | 1 | 2005 | 39 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 102 | 0.060 |
Why?
|
| DNA | 1 | 2005 | 95 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 132 | 0.060 |
Why?
|
| Femur | 1 | 2007 | 310 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 74 | 0.060 |
Why?
|
| Brain | 1 | 2012 | 1215 | 0.060 |
Why?
|
| Telomere-Binding Proteins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 34 | 0.060 |
Why?
|
| Hip Joint | 1 | 2009 | 388 | 0.060 |
Why?
|
| Models, Biological | 1 | 2005 | 305 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2005 | 402 | 0.050 |
Why?
|
| Shoulder Joint | 1 | 2008 | 530 | 0.050 |
Why?
|
| Emotions | 1 | 2021 | 70 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 40 | 0.040 |
Why?
|
| Prognosis | 2 | 2016 | 749 | 0.040 |
Why?
|
| Workers' Compensation | 1 | 2020 | 54 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 207 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2020 | 60 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 348 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 42 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2017 | 7 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 29 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 68 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 366 | 0.030 |
Why?
|
| Thrombosis | 1 | 2017 | 52 | 0.030 |
Why?
|
| Deoxyribonuclease I | 1 | 2016 | 2 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 10 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 95 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 1466 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 77 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 248 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 153 | 0.030 |
Why?
|
| Child | 1 | 2019 | 1178 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2014 | 12 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Fasting | 1 | 2012 | 19 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2012 | 13 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 40 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2012 | 138 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2012 | 79 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 543 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 10 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 50 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 233 | 0.020 |
Why?
|
| Herpesvirus 1, Suid | 1 | 2011 | 1 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 2011 | 2 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 19 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 112 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 235 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 62 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 194 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 91 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 294 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 176 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 299 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 123 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 4 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 15 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 29 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 56 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2010 | 28 | 0.020 |
Why?
|
| Insulin | 1 | 2010 | 79 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 99 | 0.020 |
Why?
|
| Length of Stay | 1 | 2011 | 305 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 285 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 283 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 141 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2008 | 13 | 0.020 |
Why?
|
| Neonatal Screening | 1 | 2008 | 6 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 76 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 230 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 357 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 431 | 0.020 |
Why?
|
| Infant | 1 | 2008 | 488 | 0.020 |
Why?
|
| Acetyltransferases | 1 | 2006 | 1 | 0.020 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2006 | 5 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2006 | 4 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2008 | 538 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 47 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 644 | 0.020 |
Why?
|
| Risk Factors | 1 | 2011 | 1997 | 0.020 |
Why?
|